Achieving High Cell Purity With The CTS DynaCellect Magnetic Separation System

When a cell therapy manufacturer found itself unable to push T cell purity past 40%, the stakes were clear: low purity means compromised therapies, extended timelines, and patients waiting longer for treatment. The challenge was compounded by a starting material with unusually high monocyte contamination at 35.6%, a condition that would overwhelm many isolation workflows.

By adopting the CTS DynaCellect Magnetic Separation System alongside targeted technical support and protocol optimization, the team transformed their process. Isolation efficiency climbed to an average of 86% across four donors, and cell purity ultimately reached 92.9% in the final run, with monocyte levels collapsing to just 0.1%. The closed, automated platform reduced manual handling, minimized variability, and integrated cleanly into their existing workflow. Read the full case study to explore the path from 40% to 92.9% purity.